tisagenlecleucel,axicabtagene ciloleucel
daiichi sankyo,gilead,novartis
['axi-cel', 'axicel', 'tisa-cel', 'lymsm']
risk factors for icans post car-t: patel et al
- 8 us centres
- icans assoc worse survival with tisa-cel, not axi-cel
- baseline crp assoc with icans
- crs is a risk, esp higher grade (e.g. g3)
important to assess risk if considering op based thearpy.
#ash22 #lymsm 
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.